Get the Stockscreener App
60.13
0.52%
0.31
Pre-market:
60.16
0.03
+0.05%
Vaxcyte Inc stock is traded at $60.13, with a volume of 1.49M.
It is up +0.52% in the last 24 hours and up +8.77% over the past month.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
See More
Previous Close:
$59.82
Open:
$60.29
24h Volume:
1.49M
Relative Volume:
1.07
Market Cap:
$8.65B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-13.07
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
-4.62%
1M Performance:
+8.77%
6M Performance:
+87.03%
1Y Performance:
-14.39%
1-Day Range:
$59.11
$62.27
1-Week Range:
$58.53
$62.73
52-Week Range:
$27.66
$76.61
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
60.13 | 8.61B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte (NASDAQ: PCVX) CTO reports stock awards and tax-related share disposals - Stock Titan
Vaxcyte (PCVX) CEO receives large RSU and option grants, surrenders shares for tax - Stock Titan
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate - TipRanks
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)? - Yahoo Finance
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. - inkl
Vaxcyte, Inc. (PCVX) - DirectorsTalk Interviews
Vaxcyte, Inc. $PCVX Shares Sold by TD Asset Management Inc - MarketBeat
Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists - Yahoo Finance
A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds - Yahoo Finance
Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
PCVX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Volatility - simplywall.st
Analysts’ Top Healthcare Picks: Vaxcyte (PCVX), TransMedics Group (TMDX) - The Globe and Mail
Westfield Capital Management Co. LP Purchases 663,817 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vanguard Group Inc. Has $443.78 Million Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (PCVX): BTIG Raises Price Target, Maintains Buy Rating | - GuruFocus
JPMorgan Chase & Co. Has $56.37 Million Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans - TipRanks
BTIG raises Vaxcyte price target to $89 on vaccine breadth edge - Investing.com Nigeria
Vaxcyte (NASDAQ:PCVX) Shares Gap Down Following Weak Earnings - MarketBeat
Leerink raises Vaxcyte stock price target on vaccine pipeline expansion By Investing.com - Investing.com Canada
Leerink raises Vaxcyte stock price target on vaccine pipeline expansion - Investing.com Nigeria
Vaxcyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ... By GuruFocus - Investing.com Canada
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and Strategic Advancements - GuruFocus
Vaxcyte Q4 Earnings Call Highlights - MarketBeat
Vaxcyte (NASDAQ:PCVX) Issues Quarterly Earnings Results - MarketBeat
Vaxcyte Q4 2025 Earnings Call Transcript - MarketBeat
Vaxcyte Launches New $500 Million ATM Equity Program - TipRanks
PCVX: VAX-31 advanced in late-stage trials, with strong financials and manufacturing readiness for 2026 - TradingView
Vaxcyte enters into sales agreement, may sell shares of common stock of up to $500 million - marketscreener.com
Vaxcyte Enters Into Sales Agreement, May Sell Shares Of Common Stock Of Up To $500 Million - TradingView
Vaxcyte Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vaxcyte Q4 Loss Widens - marketscreener.com
Vaxcyte (NASDAQ: PCVX) launches $500M common stock sales plan - Stock Titan
Vaxcyte (PCVX) Advances Pneumococcal Vaccine Programs Towards Re - GuruFocus
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
All eyes on Vaxcyte earnings as pneumococcal vaccine nears pivotal data By Investing.com - Investing.com India
All eyes on Vaxcyte earnings as pneumococcal vaccine nears pivotal data - Investing.com Australia
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 74% Potential Upside in the Innovative Vaccine Sector - DirectorsTalk Interviews
Earnings Outlook For Vaxcyte - Benzinga
Aug Movers: Whats the RSI of Vaxcyte Inc stockRisk Management & Safe Entry Trade Signal Reports - baoquankhu1.vn
Volume Report: Is Vaxcyte Inc affected by consumer sentiment2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Patterns Watch: What makes UDMY stock attractive todayAnalyst Upgrade & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Retail: What hedge funds are buying MFS High Yield Municipal TrustDividend Hike & AI Powered Market Trend Analysis - baoquankhu1.vn
Hedge Fund Bets: What is the earnings history of Otter Tail Corporation2025 Technical Patterns & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Technical Analysis: Is PSMT a defensive stockPrice Action & Daily Volume Surge Signals - baoquankhu1.vn
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors - TipRanks
Vaxcyte shows market leadership with jump to 85 RS rating - MSN
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials - Finviz
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):